3,213 research outputs found

    With four Standard Model families, the LHC could discover the Higgs boson with a few fb^-1

    Get PDF
    The existence of a 4th SM family would produce a large enhancement of the gluon fusion channel of Higgs boson production at hadron colliders. In this case, the SM Higgs boson could be seen at the CERN Large Hadron Collider (LHC) via the golden mode (H->4l) with an integral luminosity of only a few fb^-1.Comment: 7 pages, 2 figures, 2 tables, references updated in v

    Cumulant based identification approaches for nonminimum phase FIR systems

    Get PDF
    Cataloged from PDF version of article.In this paper, recursive and least squares methods for identification of nonminimum phase linear time-invariant (NMP-LTI) FIR systems are developed. The methods utilize the second- and third-order cumulants of the output of the FIR system whose input is an independent, identically distributed (i.i.d.) non-Gaussian process. Since knowledge of the system order is of utmost importance to many system identification algorithms, new procedures for determining the order of an FIR system using only the output cumulants are also presented. To illustrate the effectiveness of our methods, various simulation examples are presented

    Architecting in global software engineering

    Get PDF
    Cataloged from PDF version of article.This paper summarizes the results of the First Workshop on Architecting in Global Software Engineering (GSE), which was organized in conjunction with the 6th International Conference on Global Software Engineering (ICGSE 2011). The workshop aimed to bring together researchers and practitioners for defining and advancing the state-of-the-art and state-of-the practice in architecture design of global software development systems

    Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.

    Get PDF
    IntroductionHereditary factor X (FX) deficiency is a rare bleeding disorder affecting 1:500 000 to 1:1 000 000 of individuals. Until recently, no specific replacement factor concentrate was available.AimThe aim of this study was to assess safety and efficacy of a new, high‐purity plasma‐derived FX concentrate (pdFX) in subjects with hereditary FX deficiency.MethodsSubjects aged ≥12 years with moderate or severe FX deficiency (plasma FX activity <5 IU dL−1) received 25 IU kg−1 pdFX as on‐demand treatment or short‐term prophylaxis for 6 months to 2 years. Subjects assessed pdFX efficacy for each bleed; at end‐of‐study, investigators assessed overall pdFX efficacy. Blood samples for pharmacokinetic analysis were obtained at baseline and ≥6 months. Safety was assessed by adverse events (AEs), inhibitor development and changes in laboratory parameters.ResultsSixteen enrolled subjects (six aged 12–17 years; 10 aged 18–58 years) received a total of 468 pdFX infusions. In the 187 analysed bleeds, pdFX efficacy was categorized as excellent, good, poor or unassessable in 90.9%, 7.5%, 1.1% and 0.5% of bleeds respectively; 83% of bleeds were treated with one infusion. For pdFX, mean (median; interquartile range) incremental recovery and half‐life were 2.00 (2.12; 1.79–2.37) IU dL−1 per IU kg−1 and 29.4 (28.6; 25.8–33.1) h respectively. No serious AEs possibly related to pdFX or evidence of FX inhibitors were observed, and no hypersensitivity reactions or clinically significant trends were detected in laboratory parameters.ConclusionThese results demonstrate that a dose of 25 IU kg−1 pdFX is safe and efficacious for on‐demand treatment and short‐term prophylaxis in subjects with moderate or severe hereditary FX deficiency
    corecore